zurück

Ixazomib (re-assessment: multiple myeloma, ≥ 1 prior therapy(ies), in combination with lenalidomide and dexamethasone)

Subject:

  • Active Substance: Ixazomib
  • Name: Ninlaro®
  • Therapeutic area: Multiple myeloma
  • Pharmaceutical company: Takeda GmbH

Time table:

  • Start: 01.11.2021
  • Final decision by G-BA: 21.04.2022

Final decision:

  • Hint for a non-quantifiable additional benefit (orphan drug)